LX9211 an effective tool for managing postherpetic neuralgia
Researchers have found in a new study that the investigational drug LX9211 is a novel, non-opioid treatment option for post-herpetic neuralgia.American Academy of Neurology: A study entitled “RELIEF-PHN1: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial of LX9211 in the Treatment of Postherpetic Neuralgia Pain” was presented as Emerging Science 1 presentation by...
Researchers have found in a new study that the investigational drug LX9211 is a novel, non-opioid treatment option for post-herpetic neuralgia.
American Academy of Neurology: A study entitled “RELIEF-PHN1: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial of LX9211 in the Treatment of Postherpetic Neuralgia Pain” was presented as Emerging Science 1 presentation by the researchers.
Post Herpetic Neuralgia (PHN) is a complication tied to Varicella zoster. The condition is debilitating, and pain can last for months or years after the clearance of the zoster rash. These also have side effects, including somnolence and peripheral oedema. The therapeutic options available do not provide pain relief adequately.
LX9211 is a potent, small molecule inhibitor of AAK1, adaptor-associated protein kinase 1. It is a novel, non-opioid target for managing neuropathic pain (NP).
A recent Phase 2 study found that RELIEF-DPN 1, once-daily oral administration of LX9211, significantly reduced Neuropathic Pain in patients with painful diabetic peripheral neuropathy.
So based on this background, researchers evaluated LX9211 for safety and efficacy in PHN. Researchers included adults of ≥18 years of age with prior history of Varicella zoster skin rash and PHN pain persisting for ≥3 months after healing of skin rash. The change from baseline in Average Daily Pain Score (ADPS) based on the 11-point numerical rating scale was the primary outcome measured in the study.
The results of the study could be summarised as follows:
- There was a consistent reduction in ADPS than placebo throughout the 6-week dosing period.
- This was significant when measured across the dosing period but did not reach significance at Week 6 primary endpoint.
- The most common adverse event was dizziness.
- No serious adverse events or deaths were reported in the study.
They said, “Together with the successful RELIEF-DPN 1 study, the present study supports further clinical evaluation of LX9211 as a novel, non-opioid treatment option for multiple neuropathic pain conditions.”
Further reading:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd